IJMABHR International Journal of Medical and All Body Health ResearchIJMABHR 2582-8940 Anfo Publication House 81 Immunopathogenic and therapeutic profile of Covid-19: A comprehensive approach to explore Covid-19 MaqboolShahzaib IhteshamArham MustafaMir Ahmad Talha Mohamedwaleed Inayat LangoveMuhammad Nadeem UmarMuhammad HassanAhmad HaiderMaryam RahimNaimat Ullah Abdul MBBS, Rawalpindi Medical University Rawalpindi, Pakistan House officer Rawalpindi Medical University Rawalpindi, Pakistan Postgraduate Trainee in Paediatric Department Holy Family Hospital, Rawalpindi, Pakistan 2021 2 3 27 41 01082021 16082021 CC BY-NC-SA 4.0

COVID-19 is a disease caused by the novel strain of coronavirus also known as SARS-CoV-2 initially originated in Wuhan, China. On March 11, 2019 it was officially declared as a global pandemic by WHO. The viral transmission was associated with respiratory droplets and through other bodily secretions as well. The cellular entry of virus was associated with angiotensin converting enzymes 2 receptors (ACE-2 receptors). This study was conducted from December, 2020 to March, 2021. A total of 159 studies related to immune pathogenesis and therapeutic profile of COVID-19 were included. All studies involving pharmacological therapies for treating COVID-19 were included but the studies manifesting nutritional interventions and herbal medications for treatment of COVID-19 were excluded. Various data bases like Medline/PubMed, Scopus, and web of science were used as a search engine. Fever, cough, myalgia, headache and shortness of breath were common symptoms associated with COVID-19. The clinical spectrum of disease was ranging from asymptomatic carriers to acute respiratory distress syndrome (ARDS) caused by exaggerated inflammatory response also known as cytokine storm (IL-6, IL-1, IL-8, IL-10), and hyperactivity of host immune system (innate, cellular and humoral immune system) leading to severe form of COVID-19. Various therapeutic options used to treat COVID-19 are corticosteroids, antimalarials (hydroxychloroquine and chloroquine), antivirals (Remdesivir, lopinavir/ritonavir), antibiotics (azithromycin), interleukin-6 inhibitors (tocilizumab), Plasma exchange, and finally the most effective and economical treatment is through vaccine which is now considered definitive treatment option. However, more studies are required to explore the most effective, safer and accessible treatment options to treat and prevent COVID-19.

 Covid-19cytokine stormimmunopathogenic profiletherapeutic profile References Jeevanandam J, Pal K, Danquah MK. Virus-like nanoparticles as a novel delivery tool in gene therapy. Biochimie. 2019; 157:38-47. https://doi.org/10.1016/j.biochi.2018.11.001. Aljabali AA, Sainsbury F, Lomonossoff GP, et al. Cowpea mosaic virus unmodified empty viruslike particles loaded with metal and metal oxide. Small (Weinheim an der Bergstrasse, Germany) . 2010; 6(7):818-821. https://doi.org/10.1002/smll.200902135. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation, and Treatment of Coronavirus. In StatPearls. StatPearls Publishing, 2020. https://pubmed.ncbi.nlm.nih.gov/32150360/. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2020; 91:264-266. https://doi.org/10.1016/j.ijid.2020.01.009. Woo PC, Huang Y, Lau SK, et al. Coronavirus genomics and bioinformatics analysis. Viruses. 2010; 2(8):1804-1820. https://doi.org/10.3390/v2081803. Su S, Wong G, Shi W, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends in microbiology. 2016; 24(6):490-502. https://doi.org/10.1016/j.tim.2016.03.003. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England). 2020; 395(10224):565-574. https://doi.org/10.1016/S0140-6736(20)30251-8. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine. 2020; 382(8):727-733. https://doi.org/10.1056/NEJMoa2001017. Zhan M, Qin Y, Xue X, et al. Death from Covid-19 of 23 Health Care Workers in China. The New England journal of medicine. 2020; 382(23):2267-2268. https://doi.org/10.1056/NEJMc2005696. Wadia R. Transmission routes of COVID-19 in the dental practice. British dental journal. 2020; 228(8):595. https://doi.org/10.1038/s41415-020-1547-1. Chen HX, Chen ZH, Shen HH. Sheng li xue bao: Acta physiologica Sinica. 2020; 72(5):617-630. https://pubmed.ncbi.nlm.nih.gov/33106832/. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clinical and translational medicine. 2020; 9(1):19. https://doi.org/10.1186/s40169-020-00271-z. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020; 71(15):769-777. https://doi.org/10.1093/cid/ciaa272. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases International Journal of Medical and all body Health Research www.allmedicaljournal.com 36 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020; 395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. The Lancet. Respiratory medicine. 2020; 8(5):518-526. https://doi.org/10.1016/S2213-2600(20)30121-1. Li X, Ma X. Acute respiratory failure in COVID-19: is it typical ARDS?. Critical care (London, England). 2020; 24(1):198. https://doi.org/10.1186/s13054-020-02911-9. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. Covid-19 and comorbidities: Deleterious impact on infected patients. Journal of infection and public health. 2020; 13(12):1833-1839. https://doi.org/10.1016/j.jiph.2020.07.014. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. International journal of public health. 2020; 65(5):533-546. https://doi.org/10.1007/s00038-020-01390-7. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The Covid-19 Cytokine Storm; What We Know So Far. Frontiers in immunology. 2020; 11:1446. https://doi.org/10.3389/fimmu.2020.01446. Kwee TC, Kwee RM. Chest CT in COVID-19: What the Radiologist Needs to Know. Radiographics: a review publication of the Radiological Society of North America, Inc. 2020; 40(7):1848-1865. https://doi.org/10.1148/rg.2020200159. Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. Journal of medical virology. 2020; 92(9):1449-1459. https://doi.org/10.1002/jmv.25822. Fajgenbaum DC, June CH. Cytokine Storm. The New England journal of medicine. 2020; 383(23):2255-2273. https://doi.org/10.1056/NEJMra2026131. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID -19) in Wuhan, China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020; 71(15):762-768. https://doi.org/10.1093/cid/ciaa248. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. (2020). Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & molecular immunology. 2020; 17(5):533-535. https://doi.org/10.1038/s41423-020-0402-2. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, Shi Y. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020; 160(3):261-268. https://doi.org/10.1111/imm.13223. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virology journal. 2019; 16(1):69. https://doi.org/10.1186/s12985-019-1182-0. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.), 2020; 367(6485):1444-1448. https://doi.org/10.1126/science.abb2762. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature communications. 2020; 11(1):1620. https://doi.org/10.1038/s41467-020-15562-9. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology. 2017; 39(5):529-539. https://doi.org/10.1007/s00281-017-0629-x. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020; 395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID -19 patients. Cellular & molecular immunology. 2020; 17(5):541-543. https://doi.org/10.1038/s41423-020-0401-3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020; 395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3. Li H, Xiang X, Ren H, et al. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. The Journal of infection. 2020; 80(6):646-655. https://doi.org/10.1016/j.jinf.2020.03.035. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020; 46(5):846-848. https://doi.org/10.1007/s00134-020-05991-x. Chen G, Wu D, Guo W, et al . Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation. 2020; 130(5):2620-2629. https://doi.org/10.1172/JCI137244. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory medicine. 2020; 8(4):420-422. https://doi.org/10.1016/S2213-2600(20)30076-X. Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. National Science Review, 2020. nwaa041. https://doi.org/10.1093/nsr/nwaa041. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI insight. 2019; 4(4):e123158. https://doi.org/10.1172/jci.insight.123158. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. E Bio Medicine. 2020; 55:102763. International Journal of Medical and all body Health Research www.allmedicaljournal.com 37 https://doi.org/10.1016/j.ebiom.2020.102763. Zhang YY, Li BR, Ning BT. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. Frontiers in immunology. 2020; 11:2033. https://doi.org/10.3389/fimmu.2020.02033. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020; 52(6):971-977.e3. https://doi.org/10.1016/j.immuni.2020.04.023. Thevarajan I, Nguyen T, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature medicine. 2020; 26(4):453-455. https://doi.org/10.1038/s41591-020-0819-2. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of microbiology, immunology, and infection Wei mian yu gan ran za zhi. 2020; 53(3):368--370. https://doi.org/10.1016/j.jmii.2020.03.005. Wong CK, Lam CW, Wu AK, et al . Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and experimental immunology. 2004; 136(1):95-103. https://doi.org/10.1111/j.1365-2249.2004.02415. Lau S, Lau C, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. The Journal of general virology. 2013; 94(Pt 12) :2679-2690. https://doi.org/10.1099/vir.0.055533-0. Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. The Journal of infectious diseases. 2014; 209(9):1331-1342. https://doi.org/10.1093/infdis/jit504. Schreiber G. The Role of Type I Interferons in the Pathogenesis and Treatment of covid-19. Frontiers in immunology. 2020; 11:595739. https://doi.org/10.3389/fimmu.2020.595739. Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Frontiers in immunology. 2020; 11:1049. https://doi.org/10.3389/fimmu.2020.01049. Mo HY, Xu J, Ren XL, et al. Evaluation by indirect immunofluorescent assay and enzyme linked immunosorbent assay of the dynamic changes of serum antibody responses against severe acute respiratory syndrome coronavirus. Chinese medical journal. 2005; 118(6):446-450. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. The New England journal of medicine. 2007; 357(11):1162-1163. https://doi.org/10.1056/NEJMc070348. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. The Journal of infection. 2020; 81(1):147-178. https://doi.org/10.1016/j.jinf.2020.03.012. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet. Infectious diseases. 2020; 20(5):565-574. https://doi.org/10.1016/S1473-3099(20)30196-1. Shah VK, Firmal P, Alam A, et al. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in immunology. 2020; 11:1949. https://doi.org/10.3389/fimmu.2020.01949. Tan YJ, Goh PY, Fielding BC, et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clinical and diagnostic laboratory immunology. 2004; 11(2):362-371. https://doi.org/10.1128/cdli.11.2.362-371.2004. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus research. 2014; 194:175-183. https://doi.org/10.1016/j.virusres.2014.03.018. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. The Journal of clinical investigation. 2020; 130(10):5235-5244. https://doi.org/10.1172/JCI138759. Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020; 71(15):778-785. https://doi.org/10.1093/cid/ciaa310. Zhang Y, Xu J, Jia R, et al. Protective humoral immunity in SARS-CoV-2 infected pediatric patients. Cellular & molecular immunology. 2020; 17(7):768-770. https://doi.org/10.1038/s41423-020-0438-3. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nature reviews. Immunology. 2020; 20(6):339-341. https://doi.org/10.1038/s41577-020-0321-6. Karthik K, Senthilkumar T, Udhayavel S, et al. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter Covid-19. Human vaccines & immunotherapeutics. 2020; 16(12):3055-3060. https://doi.org/10.1080/21645515.2020.1796425. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Reviews in medical virology. 2003; 13(6):387-398. https://doi.org/10.1002/rmv.405. Willey S, Aasa-Chapman MM, O'Farrell S, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology. 2011; 8:16. https://doi.org/10.1186/1742-4690-8-16. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science (New York, N.Y.) . 2017; 358(6365):929-932. https://doi.org/10.1126/science.aan6836. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses?. Microbes and infection. 2020; 22(2):72-73. https://doi.org/10.1016/j.micinf.2020.02.006. Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral immunology. 2003; 16(1):69-86. International Journal of Medical and all body Health Research www.allmedicaljournal.com 38 https://doi.org/10.1089/088282403763635465. Okba N, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerging infectious diseases. 2020; 26(7):1478-1488. https://doi.org/10.3201/eid2607.200841. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature medicine. 2020; 26(7):1033-1036. https://doi.org/10.1038/s41591-020-0913-5. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet (London, England). 2020; 395(10223):473-475. https://doi.org/10.1016/S0140-6736(20)30317-2. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G. Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference. Neuroimmunomodulation. 2002; 10(5):247-260. https://doi.org/10.1159/000069969. Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. The European respiratory journal. 1999; 14(1):218-220. https://doi.org/10.1034/j.1399-3003.1999.14a37.x. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID -19. https://www.recoverytrial.net/fles/recovery_dexamethas one_statement_160620_v2final.pdf. Villar, J. Ferrando, C. Martínez, D. et al. (2020). Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. The Lancet. Respiratory medicine. 1999; 8(3):267-276. https://doi.org/10.1016/S2213-2600(19)30417-5. Wang Y, Jiang W, He Q, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. MedRxiv, 2020. Papamanoli A, Yoo J, Grewal P, et al. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. European journal of clinical investigation. 2021; 51(2):e13458. https://doi.org/10.1111/eci.13458. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. American journal of respiratory and critical care medicine. 2018; 197(6):757-767. https://doi.org/10.1164/rccm.201706-1172OC. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS medicine. 2006; 3(9):e343. https://doi.org/10.1371/journal.pmed.0030343. Sahraei Z, Shabani M, Shokouhi, S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents. 2020; 55(4):105945. https://doi.org/10.1016/j.ijantimicag.2020.105945. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID -19?. International journal of antimicrobial agents. 2020; 55(5):105938. https://doi.org/10.1016/j.ijantimicag.2020.105938. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clinical reviews in allergy & immunology. 2012; 42(2):145-153. https://doi.org/10.1007/s12016-010-8243-x. Bonam SR, Muller S, Bayry J, et al. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy. 2020; 16(12):2260-2266. https://doi.org/10.1080/15548627.2020.1779467. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nature reviews. Nephrology. 2011; 7(12):718-729. https://doi.org/10.1038/nrneph.2011.150. Tang W, Cao Z, Han M, et. Al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ (Clinical research ed.). 2020; 369, m1849. https://doi.org/10.1136/bmj.m1849. Savarino A, Boelaert JR, Cassone A, et. Al. Effects of chloroquine on viral infections: an old drug against today's diseases?. The Lancet. Infectious diseases. 2003’ 3(11):722-727. https://doi.org/10.1016/s1473-3099(03)00806-5. Vincent MJ, Bergeron E, Benjannet S, et. Al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005; 2:69. https://doi.org/10.1186/1743-422X-2-69. Zhonghua J, He HH, Xi ZZ, et. al. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Tuberc Respir Dis.. 2020; 43(3):185-8. https://pubmed.ncbi.nlm.nih.gov/32164085/. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020; 14(1):72–73. https://doi.org/10.5582/bst.2020.01047. Cuadrado-Lavín A, Olmos JM, Cifrian JM. et. al Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21(1):472. https://doi.org/10.1186/s13063-020-04400-4. Yao X, Ye F, Zhang M. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020; 71(15):732–739. https://doi.org/10.1093/cid/ciaa237. Rodriguez-Caruncho, C. & Bielsa Marsol, I. (2014). Antimalarials in dermatology: mechanism of action, indications, and side effects. Actas dermo-sifiliograficas, 105(3), 243 –252. https://doi.org/10.1016/j.adengl.2012.10.021. Jesus, A. A. & Goldbach-Mansky, R. (2014). IL-1 blockade in autoinflammatory syndromes. Annual review of medicine, 65, 223–244. https://doi.org/10.1146/annurev-med-061512-150641.International Journal of Medical and all body Health Research www.allmedicaljournal.com 39 Monteagudo, L. A. Boothby, A. & Gertner, E. (2020). Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. ACR open rheumatology, 2(5), 276–282. https://doi.org/10.1002/acr2.11135. Ruan, Q. Yang, K. Wang, W. et al. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine, 46(5), 846–848. https://doi.org/10.1007/s00134-020-05991-x. Giavridis, T. van der Stegen, S. Eyquem, J. Hamieh, M. Piersigilli, A. & Sadelain, M. (2018). CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature medicine, 24(6), 731 –738. https://doi.org/10.1038/s41591-018-0041-7. Shakoory, B. Carcillo, J. A. Chatham, W. W. et al. (2016). Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Critical care medicine, 44(2), 275– 281. https://doi.org/10.1097/CCM.0000000000001402. Huet, T. Beaussier, H. Voisin, O. (2020). Anakinra for severe forms of COVID-19: a cohort study. The Lancet. Rheumatology, 2(7), e393 –e400. https://doi.org/10.1016/S2665-9913(20)30164-8. Wohlford, G. F. Buckley, L. F. Vecchié, A. et al. (2020). Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. Journal of cardiovascular pharmacology, 76(1), 50–52. https://doi.org/10.1097/FJC.0000000000000847. Lin, S. J. Kuo, M. L. Hsiao, H. S. & Lee, P. T. (2016). Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4 + T cells. International immunopharmacology, 40, 318–326. https://doi.org/10.1016/j.intimp.2016.09.012. Tyteca, D. Van Der Smissen, P. Mettlen, M. et al. (2002). Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Experimental cell research, 281(1), 86– 100. https://doi.org/10.1006/excr.2002.5613. Fantini, J. Chahinian, H. & Yahi, N. (2020). Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. International journal of antimicrobial agents, 56(2), 106020. https://doi.org/10.1016/j.ijantimicag.2020.106020. Sandeep, S. & McGregor, K. (2020). Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S) Protein-ACE2 Complex. Touret, F. Gilles, M. Barral, K. et al. (2020). In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS -CoV-2 replication. Scientific reports, 10(1), 13093. https://doi.org/10.1038/s41598-020-70143-6. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020; 56(1):105949. https://doi.org/10.1016/j.ijantimicag.2020.105949. Wambier CG. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". International journal of antimicrobial agents. 2021; 57(1):106175. https://doi.org/10.1016/j.ijantimicag.2020.106175. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020; 323(24):2493-2502. https://doi.org/10.1001/jama.2020.8630. Chorin E, Wadhwani L, Magnani S. et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/ azithromycin. Heart rhythm. 2020; 17(9):1425-1433. https://doi.org/10.1016/j.hrthm.2020.05.014. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England). 2013; 381(9877):1541-1550. https://doi.org/10.1016/S0140-6736(13)60250-0. Yokota S, Imagawa T, Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet (London, England). 2008; 371(9617):998-1006. https://doi.org/10.1016/S0140-6736(08)60454-7. Cao X. COVID-19: immunopathology and its implications for therapy. Nature reviews. Immunology. 2020; 20(5):269-270. https://doi.org/10.1038/s41577-020-0308-3. Kaly L, Rosner I. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases. Best practice & research. Clinical rheumatology. 2012; 26(1):157-165. https://doi.org/10.1016/j.berh.2012.01.001. Xu X, Han M, Li T. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America. 2020; 117(20):10970–10975. https://doi.org/10.1073/pnas.2005615117. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. Journal of medical virology . 2020; 92(7):814-818. https://doi.org/10.1002/jmv.25801. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. The New England journal of medicine . 2020; 383(24):2333-2344. https://doi.org/10.1056/NEJMoa2028836. Alzghari SK, Acuña VS. Supportive Treatment with Tocilizumab for COVID -19: A Systematic Review. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2020; 127:104380. https://doi.org/10.1016/j.jcv.2020.104380. Puxeddu I, Caltran E, Rocchi V, et al. Hypersensitivity reactions during treatment with biological agents. Clinical and experimental rheumatology. 2016; 34(1):129-132. Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of Inhibition of Ebola Virus RNA-International Journal of Medical and all body Health Research www.allmedicaljournal.com 40 Dependent RNA Polymerase by Remdesivir. Viruses. 2019; 11(4):326. https://doi.org/10.3390/v11040326. Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nature reviews. Microbiology. 2019; 17(10):593-606. https://doi.org/10.1038/s41579-019-0233-2. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. The Journal of biological chemistry. 2020; 295(15):4773-4779. https://doi.org/10.1074/jbc.AC120.013056. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18. Shih WJ, Yao C, Xie T. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis. Therapeutic innovation & regulatory science. 2020; 54(5):1236– 1255. https://doi.org/10.1007/s43441-020-00159-7. Wang Y, Zhou F, Zhang D, et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020; 21(1):422. https://doi.org/10.1186/s13063-020-04352-9. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine. 2017; 9(396):eaal3653. https://doi.org/10.1126/scitranslmed.aal3653. Goldman JD, Lye D, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England journal of medicine. 2020; 383(19):1827-1837. https://doi.org/10.1056/NEJMoa2015301. Porche DJ. Lopinavir/ritonavir. The Journal of the Association of Nurses in AIDS Care : JANAC. 2001; 12(2):101-104. https://doi.org/10.1016/S1055-3290(06)60137-4. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003; 63(8):769–802. https://doi.org/10.2165/00003495-200363080-00004. Rudin C, Burri M, Shen Y, et al. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. The Pediatric infectious disease journal. 2008; 27(5):431-437. https://doi.org/10.1097/INF.0b013e3181646d5a. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature reviews. Drug discovery. 2020; 19(3):149-150. https://doi.org/10.1038/d41573-020-00016-0. Chu CM, Cheng VC, Hung IF, et al.. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252–256. https://doi.org/10.1136/thorax.2003.012658. Cao B, Wang Y, Wen D, Liu W. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine. 2020; 382(19):1787-1799. https://doi.org/10.1056/NEJMoa2001282. Gérard A, Romani S, Fresse A. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020; 75(4):371-379. https://doi.org/10.1016/j.therap.2020.05.002. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing, China). 2020; 6(10):119-1198. https://doi.org/10.1016/j.eng.2020.03.007. Wu R, Wang L, Kuo HD et al. An Update on Current Therapeutic Drugs Treating COVID-19. Current pharmacology reports, 2020, 1–15. Advance online publication. https://doi.org/10.1007/s40495-020-00216-7 Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M. Savory, E. & Stebbing, J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England). 2020; 395(10223):e30–e31. https://doi.org/10.1016/S0140-6736(20)30304-4. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. The Journal of infection. 2020; 81(2):318–356. https://doi.org/10.1016/j.jinf.2020.04.017. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti -inflammatory treatments. The Lancet. Infectious diseases. 2020; 20(4):400–402. https://doi.org/10.1016/S1473-3099(20)30132-8. El Jammal, T Gerfaud-Valentin M, Sève P, Jamilloux, Y. Les inhibiteurs de JAK : perspectives pour la médecine interne [JAK inhibitors: Perspectives in internal medicine]. La Revue de medecine interne. 2019; 40(12):816-825. https://doi.org/10.1016/j.revmed.2019.07.016. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral research, 2020, 178, 104791. https://doi.org/10.1016/j.antiviral.2020.104791. Billiau A. The interferons: a brief introduction. The Medical clinics of North America, Suppl, 1986, 7–11. https://doi.org/10.1016/s0025-7125(16)36781-5. Kalafateli M, Kourakli A, Gatselis N, Lambropoulou P. Thomopoulos K. Efficacy of Interferon A-2b Monotherapy in B-Thalassemics with Chronic Hepatitis C. Journal of Gastrointestinal & Liver Diseases. 2015; 24:2. Hung IF, Lung KC, Tso EY. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (London, England) . 2020; 395(10238):1695-1704. https://doi.org/10.1016/S0140-6736(20)31042-4. Klok FA, Kruip M, Van Der Meer N. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020; 191:145-147. https://doi.org/10.1016/j.thromres.2020.04.013. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients International Journal of Medical and all body Health Research www.allmedicaljournal.com 41 with novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH. 2020; 18(4):844-847. https://doi.org/10.1111/jth.14768. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of thrombosis and haemostasis: JTH. 2020; 18(6):1421–1424. https://doi.org/10.1111/jth.14830. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis: JTH. 2020; 18(5):1094-1099. https://doi.org/10.1111/jth.14817. Negri EM, Piloto BM, Morinaga LK, Jardim C, Lamy S, Ferreira MA, D'Amico EA et al. Heparin Therapy Improving Hypoxia in COVID-19 Patients - A Case Series. Frontiers in physiology. 2020; 11:573044. https://doi.org/10.3389/fphys.2020.573044. Turshudzhyan A. Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy. Cureus. 2020; 12(5):e8150. https://doi.org/10.7759/cureus.8150. Coppola A, Lombardi M, Tassoni MI, Carolla G, Tala M, Morandini R, Paoletti O, Testa S. COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence. Blood transfusion Trasfusione del sangue. 2020; 18(3):226-229. https://doi.org/10.2450/2020.0113-20. Tiberghien P, de Lamballerie X, Morel P, Gallian P. Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox sanguinis. 2020; 115(6):488-494. https://doi.org/10.1111/vox.12926. Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020l; 323(16):1561-1562. https://doi.org/10.1001/jama.2020.4940. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. The Journal of clinical investigation. 2020; 130(4):1545-1548. https://doi.org/10.1172/JCI138003. Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springer Plus. 2015; 4:709. https://doi.org/10.1186/s40064-015-1490-9. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004; 10(7):676-678. https://doi.org/10.1111/j.1469-0691.2004.00956.x. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. https://doi.org/10.1001/jama.2020.4783. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ (Clinical research ed.). 2020; 369, m1375. https://doi.org/10.1136/bmj.m1375. Fassett MJ, Lurvey LD, Yasumura L, et al. Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization. American journal of perinatology. 2020; 37(11):111-1114. https://doi.org/10.1055/s-0040-1714060. Umakanthan S, Chattu VK, Ranade AV, Das D, Basavarajegowda A, Bukelo M. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. AIMS public health. 2021; 8(1):137-153. https://doi.org/10.3934/publichealth.2021011. Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PloS one. 2012; 7(7):e40385. https://doi.org/10.1371/journal.pone.0040385. Banerji A, Wickner PG, Saff R. et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. The journal of allergy and clinical immunology. In practice. 2020; S2213-2198(20)31411-2. Advance online publication. https://doi.org/10.1016/j.jaip.2020.12.047. Oliver SE, Gargano JW, Marin M. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR. Morbidity and mortality weekly report . 2020; 69(50):1922-1924. https://doi.org/10.15585/mmwr.mm6950e2. Polack FP, Thomas SJ, Kitchin N. et al. Safety and Efficacy of the BNT162b2 mRNA Covid -19 Vaccine. The New England journal of medicine. 2020; 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577.